STOCK TITAN

Director at Core Laboratories (NYSE: CLB) gains new share awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Core Laboratories director Curt Anastasio reported routine equity compensation activity involving restricted shares and common stock. He received a grant of 7,895 Restricted Shares that will vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance.

These Restricted Shares are subject to a deferral election under Treasury Regulation 1.409A-2, with vested shares to be distributed as common stock following his separation of service from the Board. He also exercised 8,069 Restricted Shares that had vested after a one-year vesting period ending April 1, 2026, receiving 8,069 shares of Common Stock and bringing his directly held common shares to 23,805. The filing shows acquisitions and exercises only, with no open-market buying or selling.

Positive

  • None.

Negative

  • None.
Insider ANASTASIO CURT
Role Director
Type Security Shares Price Value
Grant/Award Restricted Shares 7,895 $0.00 --
Exercise Restricted Shares 8,069 $0.00 --
Exercise Common Stock 8,069 $0.00 --
Holdings After Transaction: Restricted Shares — 7,895 shares (Direct); Common Stock — 23,805 shares (Direct)
Footnotes (1)
  1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.
Restricted Shares granted 7,895 Restricted Shares Grant on April 1, 2026 with vesting April 1, 2027
Restricted Shares exercised 8,069 Restricted Shares Exercise on April 1, 2026 from one-year vesting period ending April 1, 2026
Common Stock after transactions 23,805 shares Directly held by Curt Anastasio following the reported transactions
Vesting date for new grant April 1, 2027 End of one-year vesting period for 7,895 Restricted Shares
Restricted Shares financial
"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"
Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.
vesting period financial
"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"
A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.
deferral election financial
"Such shares remain subject to a deferral election by the Reporting Person"
Treasury Regulation 1.409A-2 financial
"in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed"
separation of service financial
"will be distributed as shares of common stock following the Reporting Person's separation of service from the Board"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ANASTASIO CURT

(Last)(First)(Middle)
6316 WINDFERN ROAD

(Street)
HOUSTON TEXAS 77040

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026M8,069A$023,805D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Shares$004/01/2026A7,895 (1) (1)Common Stock7,895$07,895D
Restricted Shares$004/01/2026M8,069 (2) (2)Common Stock8,069$00D
Explanation of Responses:
1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.
2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.
/s/ Mark Tattoli, Attorney-in-Fact04/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did CLB director Curt Anastasio report?

Curt Anastasio reported equity compensation activity, including a grant of 7,895 Restricted Shares and the exercise of 8,069 Restricted Shares into Common Stock. All reported moves are acquisitions or exercises, with no open-market purchases or sales disclosed in this filing.

How many Core Laboratories (CLB) Restricted Shares were granted?

The filing shows a grant of 7,895 Restricted Shares to director Curt Anastasio. These shares are part of his equity compensation and are scheduled to vest after a one-year vesting period ending on April 1, 2027, subject to the terms of issuance.

When do Curt Anastasio’s new CLB Restricted Shares vest?

The newly granted 7,895 Restricted Shares vest at the end of a one-year vesting period on April 1, 2027. Vesting is subject to the terms of issuance and occurs without performance criteria, according to the footnote in the filing.

What Restricted Shares did Curt Anastasio exercise into CLB common stock?

He exercised 8,069 Restricted Shares that had vested after a one-year vesting period ending April 1, 2026. This exercise converted the vested Restricted Shares into 8,069 shares of Core Laboratories common stock at a stated price of $0.00 per share.

How many Core Laboratories (CLB) common shares does Curt Anastasio hold after these transactions?

After exercising vested Restricted Shares, Curt Anastasio directly holds 23,805 shares of Core Laboratories common stock. This total reflects the addition of 8,069 common shares from the exercise of previously vested Restricted Shares reported in the filing.

What is the deferral election mentioned for Curt Anastasio’s CLB Restricted Shares?

The filing notes the Restricted Shares remain subject to a deferral election under Treasury Regulation 1.409A-2. Vested shares will be distributed as common stock only after Curt Anastasio’s separation of service from the Board, delaying delivery beyond the vesting date.